Concepedia

Robert M. Sharkey

RM

185

Publications

14K

Citations

63

H-Index

1965

Active since

Affiliations

Center for Molecular Medicine and Immunology(Current)

Immunomedics (United States)

Radboud University Nijmegen

Radboud University Medical Center

Cornell University

Robert M. Sharkey is an author at Center for Molecular Medicine and Immunology specializing in medicine, oncology, and cancer research.

ORCID

Top concepts

Publications per year

1965–2024

185

Publications

185

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat et al. · New England Journal of Medicine · 2019 · 815 citations

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan et al. · Oncotarget · 2015 · 447 citations · Full text

A Novel Method of <sup>18</sup>F Radiolabeling for PET

William J. McBride, Robert M. Sharkey, Habibe Karacay et al. · Journal of Nuclear Medicine · 2009 · 400 citations · Full text

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond et al. · Journal of Clinical Oncology · 2017 · 386 citations

, , +13

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio et al. · Annals of Oncology · 2021 · 349 citations

Rows per page

1–5 of 185